STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst
Why this matters: health reporting relevant to everyday decisions and well-being.
At first, Pfizer’s offer to buy obesity startup Metsera was $7.3 billion. Then Novo Nordisk entered the fray with an unsolicited bid for $9 billion. Then it was a $10 billion counteroffer. A bidding war like that is an investor’s dream, and it happened to Clive Meanwell. Now, he’s betting on AI to help him do it again. The onetime oncologist has worked in drug development and biotech investment for close to four decades, and he’s now investing in big ideas with firm Population Health Partners, where he’s chairman and partner.  The firm looks for the biggest problems facing human health, problems that could yield a handsome return on investment when solved. “Then we ask the question, ‘Is there anywhere in the world a technology, or a new business model, or a molecule or two or three, or a class of drugs or diagnostics that could solve this problem?’” he said.Continue to STAT+ to read the full story…